• Serve as overall clinical program owner for oligonucleotide therapeutic programs, driving them from IND submission through clinical proof-of-concept, pivotal studies, and regulatory engagement • Define and lead the clinical development strategy for programs targeting PNS and other relevant indications • Design and oversee early- and late-stage clinical trials (IIT, Phase 1–3) for siRNA therapeutics • Partner with preclinical and translational biology teams to connect mechanistic and biomarker data with clinical endpoints • Oversee cross-functional execution of clinical trials, ensuring alignment across clinical operations, biostatistics, regulatory, and CMC functions • Guide site selection and operational planning across both U.S. and international locations • Lead preparation and review of clinical sections of INDs, Investigator’s Brochures, and regulatory briefing documents • Build and manage productive relationships with CROs, investigators, and KOLs • Inspire and lead multidisciplinary teams, ensuring alignment and collaboration across R&D, clinical, and corporate functions